Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2001

View Archived Issues

Lexicon Genetics reaches milestone in drug development alliance with Bristol-Myers Squibb

Phase II clinical data for secretin presented at Autism Society meeting

Elan licenses European rights to DepoCyte from SkyePharma

Thalomid to be submitted for new indication this year

Two recent clinical studies do not support the use of dopamine D1/5 antagonists in cocaine abuse

Randomized trial shows that cranberry juice prevents recurrence of UTI

Safety and efficacy of finasteride similar in younger and older men

Proton pump inhibitors provide the best heartburn relief

Medarex enters antibody collaboration with Human Genome Sciences

Prana Biotechnology awarded a START grant for AD drug development

OxyContin labeling changes reflect new FDA warnings

ViaCell acquires Cerebrotec

Feasibility of s.c. vaccination with VAQTA demonstrated

Head-to-head osteoporosis fracture study comparing Evista and Fosamax

Immediate pain following i.m. injection of QS-21 may be alleviated with certain excipients

Stand-alone package of Rebetol approved in U.S.

FDA advisory committee does not recommend approval of Symlin

MedImmune begins additional study of siplizumab in psoriasis patients

Two new Zonagen erectile dysfunction products evaluated in phase II trials

CancerVax to seek marketing approval of Canvaxin melanoma vaccine in Canada

New anticoagulants particularly suited for thrombosis and heparin-associated thrombocytopenia

Agouron's new rotamase-inhibitory neurotrophic agents

New adenosine derivatives with cardiac effects reported by CV Therapeutics

Selective JNK modulators and their use described by ARS

Abbott patents new series of peptide angiogenesis inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.